On September 24, Charles River Laboratories rose 5.33% in regular trading, trading at approximately $292.73 per share, with turnover of $1.29 billion. The rally was driven by the company reaffirming its full-year earnings guidance at the upper end of its prior range while unveiling medium-to-long-term growth projections through 2030.

Specifically, the company reaffirmed that its fiscal non-GAAP adjusted EPS will land at the upper end of the $11.15 to $11.45 range, above the FactSet analyst consensus estimate of $11.33. Full-year revenue growth guidance was also reaffirmed at the upper end of the 0% to 1% range. More significantly, the company issued its first long-range plan, targeting a low-double-digit compound annual EPS growth rate and 5% to 7% compound annual revenue growth from fiscal year through 2030.

The announcement comes amid a wave of analyst upgrades. Argus Research recently raised its price target to $330 from $250, JPMorgan upgraded the stock to Overweight with a $310 target, and Evercore ISI lifted its target to $320. Earlier, Q2 results beat estimates with EPS of $3.02 versus the $2.74 consensus and revenue of $1.004 billion versus the $977.2 million estimate, reinforcing confidence in the company's trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)